Ligand Pharmaceuticals | LGND - Net Income


Ligand Pharmaceuticals reported $117.27M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Agenus USD -25.27M 20.59M Mar/2025
Amgen USD 1.33B 1.88B Dec/2025
Anika Therapeutics USD -4.87M 16.99M Mar/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
Baxter International USD -1.13B 1.08B Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Enviri Corporation USD -127.97M 114.8M Dec/2024
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Insmed USD -328.48M 41.54M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Pacira USD 5.43M 10.28M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Veracyte USD 41.15M 22.01M Dec/2025